CAR-T Meeting 2024 | The optimal sequencing of CAR-T and other immunotherapies in multiple myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, comments on the optimal sequencing of CAR T-cell therapy and other immunotherapies, namely bispecific antibodies (bsAb), in patients with multiple myeloma (MM). BCMA-targeted CAR-T should be administered as early as possible in the treatment pathway due to a lower associated risk of T-cell exhaustion and infection than continuous bsAb administration. If relapse occurs, Dr Popat suggests the preferential use of a GPRC5D-targeting bsAb such as talquetamab. Additionally, the antibody-drug conjugate belantamab mafodotin can be an effective treatment option both prior to and following CAR-T due to its distinct mechanism of action. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Consultancy, Honoraria, Research Funding; Janssen: Honoraria; BMS: Honoraria; AbbVie: Honoraria; Roche: Honoraria; University College London Hospitals NHS Foundation Trus: Current Employment. Gironella: Janssen: Consultancy, Honoraria; GSK: Consultancy.
